Literature DB >> 18553185

[Immunologic control parameters during specific immunotherapy].

H Ott1, M Wosnitza, H F Merk.   

Abstract

In vivo-methods used for clinical follow-up control during specific immunotherapy (SIT) are associated with the risk of potentially severe reactions. As a safe diagnostic alternative, several in vitro-methods are currently available permitting the evaluation of immunomodulatory SIT effects. The basophil activation test, the lymphocyte transformation test and fluorescence immunoassays detecting allergen-specific IgG- and IgG4-antibodies have been utilized for this purpose. However, a reliable correlation of an immunological follow-up parameter with clinical efficacy of SIT has not been established. Therefore, further controlled studies are needed to evaluate the clinical usefulness of the described in vitro-techniques. In the future, a combination of different diagnostic methods defining sequential immunological modifications could lead to the identification of an in vitro profile characteristic of a successful SIT.

Mesh:

Substances:

Year:  2008        PMID: 18553185     DOI: 10.1007/s00105-008-1492-4

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  37 in total

Review 1.  Mechanisms of allergen specific immunotherapy--T-cell tolerance and more.

Authors:  M Jutel; M Akdis; K Blaser; C A Akdis
Journal:  Allergy       Date:  2006-07       Impact factor: 13.146

2.  Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity.

Authors:  James N Francis; Louisa K James; Giannis Paraskevopoulos; Cheukyee Wong; Moises A Calderon; Stephen R Durham; Stephen J Till
Journal:  J Allergy Clin Immunol       Date:  2008-04-18       Impact factor: 10.793

3.  Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy.

Authors:  E Mamessier; J Birnbaum; P Dupuy; D Vervloet; A Magnan
Journal:  Clin Exp Allergy       Date:  2006-06       Impact factor: 5.018

4.  Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings.

Authors:  P W Ewan; J Deighton; A B Wilson; P J Lachmann
Journal:  Clin Exp Allergy       Date:  1993-08       Impact factor: 5.018

5.  IgG subclass antibody response in grass pollen-allergic patients undergoing specific immunotherapy. Prognostic value of serum IgG subclass antibody levels early in immunotherapy.

Authors:  R Djurup; O Osterballe
Journal:  Allergy       Date:  1984-08       Impact factor: 13.146

Review 6.  Mechanisms of allergen-specific immunotherapy.

Authors:  Mübeccel Akdis; Cezmi A Akdis
Journal:  J Allergy Clin Immunol       Date:  2007-02-26       Impact factor: 10.793

7.  Mononuclear blood cell sulfidoleukotriene generation in the presence of interleukin-3 and whole blood histamine release in honey bee and yellow jacket venom allergy.

Authors:  F E Maly; S Marti-Wyss; S Blumer; I Cuhat-Stark; B Wüthrich
Journal:  J Investig Allergol Clin Immunol       Date:  1997 Jul-Aug       Impact factor: 4.333

Review 8.  Regulatory T cells in allergy and asthma.

Authors:  Mark Larché
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

9.  The CD63 basophil activation test in Hymenoptera venom allergy: a prospective study.

Authors:  G J Sturm; E Böhm; M Trummer; I Weiglhofer; A Heinemann; W Aberer
Journal:  Allergy       Date:  2004-10       Impact factor: 13.146

10.  Clinical usefulness of microarray-based IgE detection in children with suspected food allergy.

Authors:  H Ott; J M Baron; R Heise; C Ocklenburg; S Stanzel; H-F Merk; B Niggemann; K Beyer
Journal:  Allergy       Date:  2008-11       Impact factor: 13.146

View more
  1 in total

Review 1.  [In vitro diagnosis and monitoring of Hymenoptera venom hyposensitization].

Authors:  M M Neis; G Wurpts; L Wilbers; H F Merk
Journal:  Hautarzt       Date:  2011-09       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.